Search

Lutetium Lu-177 vipivotide tetraxetan

[L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533]

Respiratory syncytial virus vaccine, adjuvanted

[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]

Aflibercept

[L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in

Bevacizumab

L63807,L53213] Several biosimilars of bevacizumab also exist, including bevacizumab-awwb, bevacizumab-maly, bevacizumab-adcd, and bevacizumab-tnjn, and the Avastin biosimilar Avzivi was approved by the EMA … [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically

Zeatin

(Grant & Hackh's Chemical Dict, 5th ed)

Dorzolamide

Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an...

TJ003234

Ergocalciferol

Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as ...

Sulbactam

Sulbactam is a beta (β)-lactamase inhibitor and a derivative of the basic penicillin nucleus. When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resis...

Nigericin

(From Merck Index, 11th ed)